Photocure (NO: PHOTO)

Last close As at 26/04/2024

150.90

0.00 (0.00%)

Market capitalisation

4,048m

Edison Investment Research is terminating coverage on Photocure. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | Update

Photocure — Buying back rights from Ipsen

Healthcare | Update

Photocure — Firing on all cylinders

Healthcare | Update

Photocure — US sales up 53% compared to last year

Healthcare | Update

Photocure — US continues to be the driver

Financials

Edison Investment Research is terminating coverage on Photocure. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Research

research

Healthcare

Photocure — Positive CMS draft rule change

Update

Healthcare

Photocure — A strong quarter in the US

Update

Healthcare

Photocure — Phase III surveillance trial successful

Update

Healthcare

Photocure — Looking at other strategic opportunities

research

Healthcare

Photocure — Update 27 February 2017

Update

Healthcare

Photocure — Update 21 November 2016

Outlook

Healthcare

Photocure — Update 21 September 2016

Update

Healthcare

Photocure — Update 25 May 2016

Update

Healthcare

Photocure — Update 6 March 2016

Update

Healthcare

Photocure — Update 11 November 2015

thematic

Healthcare

Machine learning in drug development

cell DNA double helix

thematic

Healthcare

Cell and gene therapies

thematic

Healthcare

Drug delivery platforms

thematic

Healthcare

Neuroscience comeback

thematic

Consumer

IPO apocalypse

thematic

Healthcare

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

ESG, moving beyond the box tick

thematic

Healthcare

Artificial intelligence in drug discovery

thematic

Healthcare

Edison Exhibits- antibiotic development

thematic

Healthcare

The next wave in AMD

thematic

Healthcare

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

Drug pricing – Market access and reimbursement

thematic

Healthcare

The diagnostics sector

thematic

Healthcare

ASCO 2017

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Energy & Resources

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

Edison healthcare quarterly: Crisis? What crisis?